SCHEMBL14580321

SCHEMBL14580321

Nc1ccn(C2C=CC(CO)O2)c(=O)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.55
THRB P10828 1/20 0.55
MTOR P42345 1/20 0.55
MDM2 Q00987 1/20 0.55
NCOA1 Q15788 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
PDE3A Q14432 3/20 0.53
ALB P02768 3/20 0.53
CACNA1F O60840 2/20 0.53
MAPT P10636 2/20 0.53
CACNA1D Q01668 2/20 0.53
CACNA1S Q13698 2/20 0.53
CACNA1C Q13936 2/20 0.53
PDE4D Q08499 1/20 0.52
SLC29A1 Q99808 1/20 0.52
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ADRA1A P35348 1/20 0.45
BLM P54132 1/20 0.45
NT5E P21589 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7154210 1.00 LMNA (0.55) LMNATHRBMTORMDM2NCOA1
SCHEMBL1980249 1.00 LMNA (0.55) LMNATHRBMTORMDM2NCOA1
SCHEMBL5821 1.00 LMNA (0.55) LMNATHRBMTORMDM2NCOA1
SCHEMBL31662024 0.87 LMNA (0.47) LMNATHRBMTORMDM2NCOA1
SCHEMBL8644096 0.84 LMNA (0.45) LMNATHRBMTORMDM2NCOA1
SCHEMBL1739891 0.81 POLG (0.48) LMNATHRBMTORMDM2NCOA1
SCHEMBL4285392 0.81 LMNA (0.43) LMNATHRBMTORMDM2NCOA1
SCHEMBL10510561 0.80 HRAS (0.44) LMNATHRBMTORMDM2NCOA1
SCHEMBL10512002 0.80 DUT (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL10512094 0.78 NLRP3 (0.44) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037977-A1 Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties BELLEAU BERNARD 2007-02-15 US disclosed
US-20070037977-A1 Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties BELLEAU BERNARD 2007-02-15 US disclosed
US-20070037975-A1 Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties BELLEAU BERNARD 2007-02-15 US disclosed
US-20070037975-A1 Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties BELLEAU BERNARD 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037977-A1 Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties IFNAR1, MAVS, IFNG LMNA 4245/4885THRB 3658/4885MTOR 1372/4885
US-20070037975-A1 Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties IFNAR1, MAVS, IFNG LMNA 4227/4885THRB 3607/4885MTOR 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.